Abbott, AstraZeneca Submit New Drug Application to the FDA for the Approval of CERTRIAD
By admin - Posted on June 4th, 2009
Tagged: Abbott
• AstraZeneca
• Business
• FDA
• Health care
• Pharmaceutical industry
• Pharmaceuticals
Used for the Treatment of Mixed Dyslipidemia
June 4, 2009 -- AstraZeneca and Abbott announced today that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL cholesterol (the “bad” cholesterol), high triglycerides and low HDL-cholesterol (the “good” cholesterol).
The NDA submission for this investigational compound, containing the active ingredients of CRESTOR (rosuvastatin calcium) and TRILIPIX (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD.
“This NDA submission is an important milestone in the development of CERTRIAD and demonstrates our commitment to developing treatments for dyslipidemia,” said Howard Hutchinson, Chief Medical Officer, AstraZeneca. “We look forward to continued discussions with the FDA about this potential new medicine."
"Patients with mixed dyslipidemia are an underserved segment of the dyslipidemic population," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott. “If approved, CERTRIAD could become an important treatment option for physicians looking to provide comprehensive management of mixed dyslipidemia to their patients.”
According to the American Heart Association, more than 100 million adults in the United States have dyslipidemia. Of those, approximately 34 million people are affected by mixed dyslipidemia. Treatment guidelines endorsed by the National Cholesterol Education Program (NCEP), the American College of Cardiology and the American Heart Association have called for more aggressive management of lipids, including a lower LDL goal for many patients, as well as more aggressive management of HDL and triglycerides.
Source: AstraZeneca
Scroll down for related articles:
Related articles
- 2009-06-04: Abbott, AstraZeneca Submit New Drug Application to the FDA for the Approval of CERTRIAD
- 2009-11-17: Genzyme FDA Response Letter on Lumizyme Application
- 2009-10-20: FDA approves GlaxoSmithKline’s Votrient for advanced renal cell cancer
- 2009-10-08: Novartis completes shipment of US supply of Fluvirin® seasonal influenza vaccine
- 2009-10-08: Genzyme Receives FDA Complete Response Letter for Clolar
- 2009-07-02: AstraZeneca get European go-ahead for lung cancer drug
- 2009-06-22: Merck Responds to FDA on Leukotriene Inhibitors
- 2009-06-18: New biological therapy Ilaris® approved in US to treat children and adults with CAPS, a life-long auto-inflammatory disease
- 2009-06-01: AstraZeneca and Merck & Co., Inc. Join Forces to Investigate Novel Combination Anticancer Regimen
- 2009-06-01: GlaxoSmithKline: FDA Advisory Panel Makes Favorable Recommendation For ARZERRA (Ofatumumab)
- 2009-06-01: Novartis: FDA Approves Reclast To Prevent Osteoporosis In Postmenopausal Women
- 2009-05-29: Johnson & Johnson: FDA Issues Complete Response Letter for Rivaroxaban
